<html xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta name=Title content="THE PRIVATE SALE OF CANCER DRUGS IN ONTARIO’S PUBLIC">
<meta name=Keywords content="">
<meta http-equiv=Content-Type content="text/html; charset=macintosh">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 10">
<meta name=Originator content="Microsoft Word 10">
<link rel=File-List href="abstractFLOODHARDCASTLE_files/filelist.xml">
<title>THE PRIVATE SALE OF CANCER DRUGS IN ONTARIO’S PUBLIC</title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Simon Grant</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>Simon Grant</o:LastAuthor>
  <o:Revision>1</o:Revision>
  <o:Created>2007-04-03T01:32:00Z</o:Created>
  <o:LastSaved>2007-04-03T01:34:00Z</o:LastSaved>
  <o:Pages>1</o:Pages>
  <o:Lines>1</o:Lines>
  <o:Paragraphs>1</o:Paragraphs>
  <o:Version>10.260</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:Zoom>120</w:Zoom>
  <w:DisplayHorizontalDrawingGridEvery>0</w:DisplayHorizontalDrawingGridEvery>
  <w:DisplayVerticalDrawingGridEvery>0</w:DisplayVerticalDrawingGridEvery>
  <w:UseMarginsForDrawingGridOrigin/>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
@font-face
	{font-family:"Times New Roman";
	panose-1:0 2 2 6 3 5 4 5 2 3;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:50331648 0 0 0 1 0;}
@font-face
	{font-family:Arial;
	panose-1:0 2 11 6 4 2 2 2 2 2;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:50331648 0 0 0 1 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:0 2 11 10 4 2 1 2 2 2;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:50331648 0 0 0 1 0;}
@font-face
	{font-family:Georgia;
	panose-1:0 2 4 5 2 5 4 5 2 3;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:50331648 0 0 0 1 0;}
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Arial;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{mso-style-update:auto;
	mso-style-next:"Normal\,Text";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Arial;}
p.Topic, li.Topic, div.Topic
	{mso-style-name:Topic;
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Arial Black";}
p.Case, li.Case, div.Case
	{mso-style-name:Case;
	mso-style-update:auto;
	mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Arial;
	font-weight:bold;}
@page Section1
	{size:8.5in 11.0in;
	margin:1.0in 1.25in 1.0in 1.25in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
</head>

<body bgcolor=white lang=EN-US style='tab-interval:.5in'>

<div class=Section1>

<p class=MsoNormal align=center style='text-align:center;mso-pagination:none;
mso-layout-grid-align:none;text-autospace:none'><span style='font-size:14.0pt;
font-family:Georgia'>THE PRIVATE SALE OF CANCER DRUGS IN ONTARIO’S PUBLIC<o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;mso-pagination:none;
mso-layout-grid-align:none;text-autospace:none'><span style='font-size:14.0pt;
font-family:Georgia'>HOSPITALS: TOUGH ISSUES AT THE PUBLIC/PRIVATE INTERFACE IN
HEALTH CARE<o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span style='font-family:Georgia'><i><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></i></span></p>

<p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span style='font-family:Georgia'><i>Colleen M. Flood</i></span><span
style='font-size:6.5pt;font-family:Georgia'><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span style='font-family:Georgia'><i>&amp; Lorian
Hardcastle</i></span><span style='font-size:6.5pt;font-family:Georgia'><o:p></o:p></span></p>

<p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span style='font-size:8.0pt;font-family:Georgia'><i><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></i></span></p>

<p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span style='font-size:8.0pt;font-family:Georgia'><i>As
increases in health care spending outpace economic growth, governments
increasingly face tough choices. One significant cost driver is the influx of
new technologies, particularly expensive drug therapies. In response,
provincial governments are increasingly scrutinizing the costs and benefits of
new drugs and determining that despite some therapeutic benefit, they are not
sufficiently beneficial to receive public funding. These choices raise complex
legal, economic, political, and ethical issues.<o:p></o:p></i></span></p>

<p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span style='font-size:8.0pt;font-family:Georgia'><i><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></i></span></p>

<p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span style='font-size:8.0pt;font-family:Georgia'><i>This
paper explores these issues as they pertain to Ontario’s recent decision not to
publicly fund three cancer drugs—Velcade, Alimta, and Zevalin. To be clear,
although not considered sufficiently cost-effective to warrant public funding
in Ontario, these drugs are of some therapeutic benefit; indeed, a physician
may strongly recommend one or more of these drugs to extend a patient’s life by
a few months. This is illustrated by the fact that the provinces of Quebec, Alberta,
and British Columbia have all elected to fund these drugs in their public
hospitals. That they have chosen public funding, when Ontario has not,
illustrates that no sharp distinctions can be drawn about what is “medically
necessary”(and thus publicly funded) and what is not.<o:p></o:p></i></span></p>

<p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span style='font-size:8.0pt;font-family:Georgia'><i><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></i></span></p>

<p class=MsoNormal style='mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span style='font-size:8.0pt;font-family:Georgia'><i>Ontario’s
decision has resulted in pressure from patients who want to buy the drugs but
have the drugs administered </i></span><span style='font-size:8.0pt;font-family:
Georgia'>within <i>public hospitals. For safety reasons, these drugs need to be
provided in hospital-like settings. Patients who can afford to pay for the drug
still find it difficult to access them because there is only one private cancer
clinic in Ontario (downtown Toronto). The Ontario government is considering
whether or not to allow private-pay drugs to be administered within public
hospitals—so that people who can afford to pay for the drugs can access them more
readily. We explore Ontario’s dilemma in three parts. First, we address how
Ontario’s statutory context permits or acts as a bar to the sale of drugs in
public hospitals. Second, we discuss the myriad of policy concerns the
government faces in deciding whether to permit the sale of cancer drugs in
public hospitals: fairness, equality, sustainability, compassion, safety, and
the effects of such a policy on the public system. Finally, given the
difficulty in obtaining these drugs safely in a private setting, we address
whether the government could be compelled to allow patients access to privately
purchased drugs in public hospitals via a successful challenge under section 7
of the </i></span><span style='font-size:8.0pt;font-family:Georgia'>Canadian
Charter of Rights and Freedoms<i>.<o:p></o:p></i></span></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

</div>

</body>

</html>
